Strides Pharma Science (STAR) Aandelenoverzicht
Strides Pharma Science Limited ontwikkelt, produceert en verkoopt farmaceutische producten in Afrika, Australië, Noord-Amerika, Europa, Azië en India. Meer informatie
| Sneeuwvlok Score | |
|---|---|
| Waardering | 4/6 |
| Toekomstige groei | 5/6 |
| Prestaties in het verleden | 4/6 |
| Financiële gezondheid | 5/6 |
| Dividenden | 3/6 |
Beloningen
Risicoanalyse
STAR Community Fair Values
Create NarrativeSee what 13 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Strides Pharma Science Limited Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | ₹1,055.50 |
| 52 Week Hoogtepunt | ₹1,231.00 |
| 52 Week Laag | ₹768.65 |
| Bèta | 0.34 |
| 1 maand verandering | -8.51% |
| 3 maanden verandering | 18.34% |
| 1 Jaar Verandering | 19.61% |
| 3 jaar verandering | 162.17% |
| 5 jaar verandering | 36.49% |
| Verandering sinds IPO | 17.85% |
Recent nieuws en updates
Narratiefupdate • Jun 01
STAR: Upcoming Results, Dividend Proposal And Auditor Change Will Shape Balanced Outlook
Analysts have kept the price target for Strides Pharma Science broadly steady at about ₹1,119, citing only small tweaks to assumptions on discount rate, revenue growth, profit margin and future P/E that do not materially change their valuation view. What's in the News A board meeting is scheduled on May 18, 2026 at 12:30 Indian Standard Time to review and approve audited standalone and consolidated financial results for the quarter and year ended March 31, 2026.
Narratiefupdate • May 17
STAR: Upcoming Results And Dividend Decision Will Shape Fairly Valued Outlook
Analysts have raised their price target on Strides Pharma Science from ₹1,078.50 to ₹1,264.00, citing updated assumptions that include higher projected revenue growth, a slightly stronger profit margin profile, a modestly lower discount rate, and a somewhat higher future P/E multiple. What's in the News A board meeting is scheduled on May 18, 2026, to review and approve the audited standalone and consolidated financial results for the quarter and full year ended March 31, 2026 (Key Developments).
Narratiefupdate • Apr 28
STAR: Higher Revenue And Margin Assumptions Will Support Stronger Returns Ahead
Analysts have maintained their price target for Strides Pharma Science at ₹1,409, citing updated assumptions that reflect slightly higher revenue growth and profit margin expectations, along with a modestly lower future P/E multiple in their models. Valuation Changes Fair Value: Model fair value remains unchanged at ₹1,409.0 per share.Recent updates
Narratiefupdate • Jun 01
STAR: Upcoming Results, Dividend Proposal And Auditor Change Will Shape Balanced Outlook
Analysts have kept the price target for Strides Pharma Science broadly steady at about ₹1,119, citing only small tweaks to assumptions on discount rate, revenue growth, profit margin and future P/E that do not materially change their valuation view. What's in the News A board meeting is scheduled on May 18, 2026 at 12:30 Indian Standard Time to review and approve audited standalone and consolidated financial results for the quarter and year ended March 31, 2026.Narratiefupdate • May 17
STAR: Upcoming Results And Dividend Decision Will Shape Fairly Valued Outlook
Analysts have raised their price target on Strides Pharma Science from ₹1,078.50 to ₹1,264.00, citing updated assumptions that include higher projected revenue growth, a slightly stronger profit margin profile, a modestly lower discount rate, and a somewhat higher future P/E multiple. What's in the News A board meeting is scheduled on May 18, 2026, to review and approve the audited standalone and consolidated financial results for the quarter and full year ended March 31, 2026 (Key Developments).Narratiefupdate • Apr 28
STAR: Higher Revenue And Margin Assumptions Will Support Stronger Returns Ahead
Analysts have maintained their price target for Strides Pharma Science at ₹1,409, citing updated assumptions that reflect slightly higher revenue growth and profit margin expectations, along with a modestly lower future P/E multiple in their models. Valuation Changes Fair Value: Model fair value remains unchanged at ₹1,409.0 per share.Narratiefupdate • Apr 13
STAR: Upcoming Results Meeting And Revised Assumptions Will Support Bullish Thesis
Analysts have lifted their price target on Strides Pharma Science from ₹1,085 to ₹1,119, pointing to revised assumptions that include slightly higher revenue growth, a modestly lower profit margin and a small uplift in the future P/E multiple. What's in the News A board meeting is scheduled for January 30, 2026 to consider and approve unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025, along with other agenda items (company filing).Narratiefupdate • Mar 30
STAR: Higher Revenue Assumptions Will Support Stronger Profit Margins Ahead
Analysts have raised their price target on Strides Pharma Science from ₹1,220 to ₹1,409, citing updated assumptions for revenue growth, profit margins and future P/E that collectively support a higher fair value estimate under a slightly lower discount rate. What's in the News A board meeting is scheduled for January 30, 2026, to consider and approve the unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025, along with other matters (company filing).Narratiefupdate • Mar 16
STAR: Future Earnings Meeting And Margin Outlook Will Support Bullish Thesis
Analysts have lifted their price target on Strides Pharma Science from ₹937 to ₹1,085, citing updated assumptions for revenue growth, profit margins and the future P/E multiple, as well as a slightly lower discount rate. What's in the News The board has scheduled a meeting on January 30, 2026 to consider and approve the unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025, along with other matters (company filing).Narratiefupdate • Sep 05
Affordable Generics And Digital Trends Will Broaden Global Healthcare Reach
With both Net Profit Margin and Revenue Growth forecasts remaining stable, analysts made no substantive changes to their outlook, resulting in the consensus price target for Strides Pharma Science holding steady at ₹1078. What's in the News Board meeting scheduled to consider and approve Q1 FY26 unaudited financial results, share allotment, and amendments to the company's fair disclosure policy.
Nieuw narratief • Feb 10
US Product Launches And ESG Leadership Will Strengthen Future Market Position
Streamlined focus on high-margin operations and U.S. market expansion indicate a strong growth trajectory and improved future earnings.Analyseartikel • Nov 01
Strides Pharma Science's (NSE:STAR) Solid Earnings Are Supported By Other Strong Factors
Even though Strides Pharma Science Limited's ( NSE:STAR ) recent earnings release was robust, the market didn't seem to...Analyseartikel • Oct 21
Why Investors Shouldn't Be Surprised By Strides Pharma Science Limited's (NSE:STAR) 27% Share Price Surge
Despite an already strong run, Strides Pharma Science Limited ( NSE:STAR ) shares have been powering on, with a gain of...Analyseartikel • Aug 14
After Leaping 29% Strides Pharma Science Limited (NSE:STAR) Shares Are Not Flying Under The Radar
Despite an already strong run, Strides Pharma Science Limited ( NSE:STAR ) shares have been powering on, with a gain of...Analyseartikel • Apr 04
Investors Still Waiting For A Pull Back In Strides Pharma Science Limited (NSE:STAR)
With a median price-to-sales (or "P/S") ratio of close to 2.4x in the Pharmaceuticals industry in India, you could be...Analyseartikel • Feb 29
Does Strides Pharma Science (NSE:STAR) Have A Healthy Balance Sheet?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Analyseartikel • Dec 23
Strides Pharma Science Limited's (NSE:STAR) Shares Leap 31% Yet They're Still Not Telling The Full Story
Strides Pharma Science Limited ( NSE:STAR ) shareholders have had their patience rewarded with a 31% share price jump...Analyseartikel • Sep 26
We Think Strides Pharma Science (NSE:STAR) Is Taking Some Risk With Its Debt
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analyseartikel • Jun 08
Does Strides Pharma Science (NSE:STAR) Have A Healthy Balance Sheet?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analyseartikel • Aug 02
Strides Pharma Science Limited (NSE:STAR) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates
Last week saw the newest quarterly earnings release from Strides Pharma Science Limited ( NSE:STAR ), an important...Analyseartikel • Jun 25
Is Strides Pharma Science (NSE:STAR) A Risky Investment?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Rendement voor aandeelhouders
| STAR | IN Pharmaceuticals | IN Markt | |
|---|---|---|---|
| 7D | 1.0% | 1.1% | 0.05% |
| 1Y | 19.6% | 6.9% | -2.0% |
Rendement versus industrie: STAR overtrof de Indian Pharmaceuticals industrie, die het afgelopen jaar een rendement 6.9 % opleverde.
Rendement versus markt: STAR overtrof de Indian markt, die het afgelopen jaar een rendement opleverde van -2 %.
Prijsvolatiliteit
| STAR volatility | |
|---|---|
| STAR Average Weekly Movement | 5.3% |
| Pharmaceuticals Industry Average Movement | 7.2% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in IN Market | 10.2% |
| 10% least volatile stocks in IN Market | 4.7% |
Stabiele aandelenkoers: STAR heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend vergeleken met de Indian markt.
Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 5% ) van STAR is het afgelopen jaar stabiel geweest.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 1990 | 3,301 | Badree Komandur | www.strides.com |
Strides Pharma Science Limited ontwikkelt, produceert en verkoopt farmaceutische producten in Afrika, Australië, Noord-Amerika, Europa, Azië en India. Het bedrijf is actief in twee segmenten, Farmaceutica en Biofarmaceutica. Het bedrijf biedt farmaceutische generieke producten in verschillende vormen, zoals tabletten, harde en zachte gelatine capsules, sachets en vloeistoffen, evenals neusspray, gels, poeders, vaste stoffen, zalven en crèmes.
Strides Pharma Science Limited Samenvatting
| STAR fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | ₹97.29b |
| Inkomsten(TTM) | ₹5.56b |
| Inkomsten(TTM) | ₹48.59b |
17.5x
Koers/Winstverhouding2.0x
P/S-verhoudingIs STAR overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| STAR resultatenrekening (TTM) | |
|---|---|
| Inkomsten | ₹48.59b |
| Kosten van inkomsten | ₹19.59b |
| Brutowinst | ₹29.00b |
| Overige uitgaven | ₹23.44b |
| Inkomsten | ₹5.56b |
Laatst gerapporteerde inkomsten
Mar 31, 2026
Volgende inkomensdatum
n.v.t.
| Winst per aandeel (EPS) | 60.34 |
| Brutomarge | 59.69% |
| Nettowinstmarge | 11.45% |
| Schuld/Eigen Vermogen Verhouding | 53.0% |
Hoe presteerde STAR op de lange termijn?
Bekijk historische prestaties en vergelijkingDividenden
0.5%
Huidig dividendrendement8%
UitbetalingsratioBedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/06/14 23:36 |
| Aandelenkoers aan het einde van de dag | 2026/06/12 00:00 |
| Inkomsten | 2026/03/31 |
| Jaarlijkse inkomsten | 2026/03/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Strides Pharma Science Limited wordt gevolgd door 14 analisten. 2 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Aditya Khemka | Ambit Capital |
| Harith Ahamed | Avendus Spark |
| Prakash Agarwal | Axis Capital Limited |